Fosun and Insilico announce strategic, AI-driven drug discovery collaboration

Latest articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

It’s time to reboot longevity and healthy aging

Dr Michael Roizen calls for fundamental societal changes to ensure the benefits of longevity and healthy aging are realised. Later this year, best-selling author Michael...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Click the globe for translations.

AI-powered, $13 million drug discovery and development collaboration set to jointly advance multiple targets.

Fosun Pharma, an innovation-driven international healthcare group based in China, and Insilico Medicine, an end-to-end AI-driven drug discovery and development company, have announced they have entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.

This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico’s QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialisation profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.

“We are pleased to enter into a strategic collaboration with Insilico,” said Yifang Wu, Chairman and CEO of Fosun. “Fosun Pharma is committed to promoting innovative R&D and is oriented towards fulfilling unmet clinical needs and improving products’ accessibility. We look forward to working with Insilico to leverage the technological and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D, and benefiting more patients worldwide [1].”

The collaboration aims to combine Insilico’s end-to-end AI-driven drug discovery platforms and Fosun Pharma’s clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics. Pursuant to the collaboration agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and expanding it to the IND stage, after which, Fosun Pharma will then conduct human clinical studies and co-develop the candidate globally.

In parallel, Fosun Pharma’s R&D team will nominate four therapeutic targets to be assessed by Insilico’s AI platform and R&D team, who are responsible for advancing drug discovery candidates to the IND stage. As part of the collaboration, Fosun Pharma will secure access to Insilico’s PandaOmics and Chemistry42 platforms in order to advance Fosun Pharma’s internal AI-powered drug discovery and development efforts.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, told Longevity.Technology that the QPCTL program, which came out of Insilico’s end-to-end AI engine, is a very promising, possibly record-setting target in immuno-oncology.

“While other companies in our space have announced partnerships around a very large number of undisclosed targets, we decided to partner on just four to ensure that we have the capacity to do more partnerships, advance the platform, and internal pipeline,” he said. “We are committed to novelty, excellence, and continuous improvement and just like we pioneered many of the technologies in use today, we strive to invent new methods, come up with disruptive ideas, and turn these ideas into platforms and therapeutic programs.”

[1] https://www.fosunpharma.com/en/news/news-details-3868.html

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Omecu aims to reduce analysis time and democratise genome data

Spinout company aims to revolutionise the handling of genome data by drastically reducing the time it takes to analyse millions of genetic records. Omecu Ltd,...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

    Subscribe to our newsletter